Investigation of Plasma C-peptide level in Prostate Cancer

Faezeh Namazi¹ Alireza Talebi² Nasrin Hadi³ Jalil Shafiee⁴ Behnaz Nateghi⁵

1) Department of Genetic, Ashkezar Branch, Islamic Azad University, Ashkezar, Yazd, Iran
2) Ph.D. student of Microbiology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
3) 3. Department of Genetic, Ashkezar Branch, Islamic Azad University, Ashkezar, Yazd, Iran
4) 4. Department of Genetic, Science and Research Branch, Islamic Azad University, Tehran, Iran
5) 5. Department of Biochemistry, Faculty of Science, Nourdanesh Institutions of Higher Learning, Meimeh, Isfahan, Iran. Email;

Publication : 4th.International Conference on Researches in Science & Engineering & International Congress on Civil, Architecture and Urbanism in Asia(4icrsie.com)
Abstract :
Prostate cancer is a biologically heterogeneous disease which has become the fifth leading cause of death from cancer in men worldwide. Recently, studies have shown that cancer biomarkers could help to improve the management of cancer. Therefore, the aim of this study was to examine the plasma C-peptide level in Iranian patients with prostate cancer. In the present study, 80 samples, including 40 patients with prostate cancer, and 40 healthy controls were collected. The level of C-peptide was investigated in prostate cancer patients and healthy controls by ELISA. Data were analyzed by SPSS software. Also, prostate cancer signaling pathway enrichment analysis performed on the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Analysis of the level of C-peptide was no statistically significant difference (P-value<0.17). However, the level of C-peptide in prostate cancer increased compared to controls. The findings of the current study revealed no association between the level of C-peptide and prognosis in prostate cancer, at least in our patients studied. However, more in-depth and comprehensive investigations should be done.
Keywords : Prostate cancer C-peptide Biomarker Prognosis.